KPV

Evaluate KPV intestinal-cell and mouse colitis studies, peptide transport and nanoparticle delivery, with clear distinctions from human treatment evidence.

MGF

Compare MGF osteoblast findings with negative muscle-cell replication research, distinguishing peptide identity, proliferation and functional tissue repair.

Selank

Evaluate Selank patient comparisons, acute brain-imaging findings and animal evidence, with clear limits on equivalence, cognitive and safety claims.

Semaglutide

Review semaglutide weight-loss trials, cardiovascular and kidney outcomes, withdrawal evidence, current product indications and safety considerations.

Semax

Review Semax rehabilitation research, acute imaging and negative animal findings without confusing biomarkers with lasting cognitive or clinical benefit.

Livagen

Review Livagen liver-explant and patient-derived cell studies, separating genomic measurements from clinical liver, cancer and cardiovascular claims.

Melanotan II

Examine Melanotan II tanning and erectile-response studies, serious safety reports, product identity and the limits of early human evidence.

NAD+

Review the NAD+ infusion pilot, distinguish precursor research from direct NAD+ evidence, and examine FDA injectable-product safety concerns.

PNC-27

Understand PNC-27 membrane-targeting research, leukemia models and FDA product warnings without mistaking experiments for an established cancer treatment.

PT-141

Review PT-141 and bremelanotide trials, the approved HSDD indication, desire and distress results, male research and important safety limits.